Eligibility of monoclonal antibody-based therapy for patients with severe asthma: a Canadian cross-sectional perspective

BackgroundBased on immunologic phenotypes underlying asthma, use of monoclonal antibody based therapies is becoming the new standard of care for severe, corticosteroid refractory clinical symptoms. Patients may qualify for one or more of these targeted treatments, based on clinical characteristics and approved indications. However, the statistics are not well characterized, particularly in the Canadian population.MethodsThe objective of this …